Physician profile
John E Paes
NPI 1912122334
$670,943.93
in general payments reported to CMS, 2019-2025
23 companies · $123K in 2025
The $123K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $70K · 2021: $67K · 2022: $90K · 2023: $84K · 2024: $142K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $259K · Honoraria: $44K · Travel and Lodging: $37K · Food and Beverage: $8,540 · Consulting Fee: $1,050 · Education: $71.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $258,994.75 |
| Honoraria | $44,450.00 |
| Travel and Lodging | $36,725.61 |
| Food and Beverage | $8,540.12 |
| Consulting Fee | $1,050.00 |
| Education | $71.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $560,509.96 | 2019-2025 | Mounjaro, Lyumjev, Zepbound |
| Xeris Pharmaceuticals, INC. | $48,543.77 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $36,312.03 | 2020-2025 | Repatha, Repatha, Tepezza |
| Esperion Therapeutics, INC. | $17,005.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $7,247.94 | 2019 | |
| Dexcom, INC. | $273.69 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $174.12 | 2020-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $172.08 | 2020-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $149.97 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $109.16 | 2023-2024 | Korlym |
| Amarin Pharma, INC. | $99.61 | 2020 | |
| Mannkind Corporation | $70.33 | 2023 | Afrezza |
| Medtronic, INC. | $69.26 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $28.65 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $25.28 | 2025 | Cequr Simplicity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.46 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.39 | 2023 | Cycloset |
| Radius Health, INC. | $21.38 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $20.11 | 2025 | Twiist |
| Ibsa Pharma INC. | $19.64 | 2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $17.64 | 2025 | |
| Nevro Corp. | $15.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.